(CercleFinance.com) – Eli Lilly announces that a phase III clinical trial has achieved its primary objective of demonstrating significant renal and cardiovascular benefit of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).
Indeed, with treatment with Jardiance, the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% compared to placebo.
These findings were announced today at the American Society of Nephrology (ASN) Kidney Week 2022 by the Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford,
“We know there is an urgent need for new therapies that have been shown to delay the progression of CKD, which may lead to the need for dialysis or a transplant,” said William Herrington , nephrologist and co-principal investigator of the trial.
“Today’s results demonstrate that Jardiance may benefit adults at risk of progression, including those with and without diabetes, and across a wide range of kidney functions,” he added.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
